Figure 6.

The histone deacetylase inhibitor sodium butyrate (SB) enhances Sp1 acetylation in vivo. Cohorts of R6/2 mice (n = 6) were treated daily with sodium butyrate (1.2 gm/kg) or PBS intraperitoneal injections for 2 weeks. Sp1 acetylation levels from homogenized brains of PBS- and sodium butyrate-treated R6/2 mice were determined by immunoprecipitation (IP) using an Sp1 antibody followed by immunoblotting using acetyl lysine (Ac-lysine) antibody (Ac-Sp1) or Sp1 antibody alone (Sp1). Sp1 acetylation was increased in sodium butyrate-treated R6/2 mice. Note that levels of Sp1 did not change with sodium butyrate treatment.